Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study

Authors:
Publisher website
Google Scholar
Abstract
Biotherapeutics are protein products generated using recombinant DNA technology and manufactured in prokaryotic or eukaryotic cells. It is often said that “the process is the product” and thereby the effect of the manufacturing process is etched on the final product in the form of its heterogeneity. For any biotherapeutic, the acceptable range of the critical quality attributes is defined based on the expected impact of a specific variation on the product stability, safety, and efficacy. For a biosimilar to receive regulatory approval, the manufacturer must demonstrate analytical and clinical comparability with the originator product. As this is mandatory, every biosimilar manufacturer performs this exercise for each biosimilar product under development. However, few reports of thorough evaluation of the quality of biosimilar products are available in the literature.
Funding Information
  • Department of Biotechnology , Ministry of Science and Technology (BT/COE/34/SP15097/2015)

This publication has 36 references indexed in Scilit: